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Chronic lymphocytic leukemia (CLL) causes early-onset immune dysregulation increasing the risk of infection, second malignancies, and 
autoimmune complications by poorly understood mechanisms. Targeted therapy has improved therapeutic outcomes but persistent 
immune deficiency remains an unresolved problem. Severe infections (20/100 patient-years) cause or contribute to over 35% of CLL-
related deaths. Most identified infections are bacterial (~70%) with the commonest blood isolates being Escherichia coli, Streptococcus 
pneumoniae, and Staphylococcus aureus. Viral infections (~25%) are disproportionately caused by Herpes viruses and influenza. Most 
common infection sites are lower respiratory tract, skin, and urogenital tract. CLL patients have an increased risk (~2-fold) of second 
malignancies with the commonest being squamous and basal cell skin cancer, melanoma, and lung cancer. There is a significantly 
increased risk of additional clonal and non-clonal non-Hodgkin lymphomas and Hodgkin lymphoma. Autoimmune cytopenias affect 
~10% of CLL patients causing anemia (hemolysis and red cell aplasia), thrombocytopenia, and neutropenia. Nonhematological 
autoimmune complications are rare. Management of these complications requires a comprehensive multidisciplinary approach 
including education, preventative medicine, active monitoring, and early diagnosis and treatment. Research to better understand CLL-
related immune defects and determine how to reverse them is essential for improved clinical care.
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Introduction
Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) 
is the most prevalent lymphoid malignancy in Europe [1] and North 
America [2] and causes considerable morbidity and mortality. CLL is 
associated with early onset and often profound immune dysregulation 
that increases the risk of infection, second malignancies, and 
autoimmune complications [3–5]. The incidence and prevalence of 
these complications are likely to increase because of population aging 
and the ongoing development of more effective but still noncurative 
therapies resulting in longer survival.
Immune dysfunction effecting both the adaptive and innate immune 
responses occurs early in the course of CLL and high-count monoclonal 
B-cell lymphocytosis (MBL) [6–8]. The mechanism by which CLL 
induces immune dysfunction is poorly understood. T cell dysfunction 
in CLL is characterized by abnormal CD4:CD8 effector ratios, skewed 
helper T cell profiles (e.g., increased Th2:Th1), impaired immune 
synapse formation, and reduced proliferative and cytotoxic activities 
characteristic of T cell exhaustion [8–11]. Humoral immune defects 
include skewed memory B and plasma cell populations that correlate 
with hypogammaglobulinemia [12, 13]. Innate immune defects include 
altered monocyte and macrophage immunophenotypes with increased 
circulating “immunosuppressive” (CD14+/HLA-DRneg-low) cells [14, 15]. 
CLL also causes impaired neutrophil function and decreases serum 
complement levels [7].
Treatment of progressive CLL with chemoimmunotherapy causes 
short-term exacerbation of CLL immunosuppression and subsequent 
immune recovery, even in patients with a large reduction of CLL 
disease burden, is limited resulting in long-term immune compromise 
[16]. Treatment with targeted therapy has less initial detrimental effect 
on immune competence compared to chemoimmunotherapy but there 
is currently no evidence of substantial recovery of immune competence 
in responding patients. Ibrutinib has been reported to reverse some 
CLL-induced immune changes. Studies have shown increased T cell 
activity, reversal of the exhaustion phenotype and Th1 skewing, and 
reduced expression of immunosuppressive molecules (CD200, BTLA, 
and IL-10) but the role of inhibition of BTK versus off-target ibrutinib 
effects (e.g., on T cell TEK family kinase ITK) is still unclear [17–19]. 
Studies of chimeric antigen receptor (CAR) T cell products, bispecific 
antibody targeted T cells, and MHC-independent gamma/delta+ T 
cells, have also pointed toward the ability of ibrutinib to promote T cell 
activation by off-target TEC protein kinase inhibition in the short-term 
[18, 20–22]. In contrast, the more specific BTK inhibitor acalabrutinib 
does not appear to have the same effects as ibrutinib on T cell subsets 
[19]. The availability of targeted therapy has greatly improved the 
outcome for many patients with CLL, but we are still not able to correct 
CLL-induced immune deficiency [23]. A better understanding of the 
complex effects of CLL on immune function will required to achieve the 
important goal of immune reconstitution.
Infection
Historically, major infections were reported to occur at least once in 
more than 50% of CLL patients and to cause or contributed to 30%–
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50% of deaths [24, 25]. Some of the more contemporary data from 
clinical trials could be biased by selective eligibility and enrollment 
of patients that are younger and fitter than the average of the CLL 
population [26, 27]. The risk and consequences of infections in CLL 
patients could also be changing because of the increasing use of less 
toxic and more effective targeted therapy [28] that have decreased 
the rate of serious infections following initiation of therapy [29]. 
With increased CLL patient survival, the lifetime risk of infections 
is increasing and complications not recognized as severe adverse 
effects by standardized criteria (e.g., shingles associated neuropathic 
pain) are causing more morbidity. The overall burden of infection in 
CLL patients is likely to remain a problem in the foreseeable future.
A recently published single-center observational study reported 
on a population of CLL patients during the transition period from 
chemoimmunotherapy to targeted therapy. Severe infections 
requiring inpatient admission or intravenous antimicrobial therapy 
had an incidence rate (IR) of 20/100 person-years and less severe 
infections occurred at a rate of 70/100 person-years [3]. The most 
common sites of severe infections were lower respiratory tract (IR 
8/100 person-years), skin (IR 3/100 person-years), and urogenital 
tract (2/100 person-years). The causative organism could be 
determined in 38% of patients with the majority being bacterial (27% 
of all infections) followed by viral (7%) and fungal (4%). Fifteen 
(38%) of 40 deaths during the study were attributable to infections. 
In treatment naive patients multivariate analysis showed that the 
risk of infection was increased in patients with more advanced 
clinical stage at diagnosis and with increased time from diagnosis. 
Patients requiring treatment for CLL had increased risk of infection 
with the highest risks on patients treated with purine analoges or 
alemtuzumab. Patients treated with ibrutinib had higher risk of 
infection compared to treatment naive patients.
Patient with CLL are reported to have a propensity to infection with 
encapsulated bacteria. A Danish study reported on 317 positive 
blood cultures in 3,822 patients, which occurred at a rate of 15.5 per 
1,000 patient-years in treatment naive and 62.3 per 1,000 patient-
years in treated patients. The most commonly isolated bacteria 
were Escherichia coli (24%), Streptococcus pneumoniae (10%) and 
Staphylococcus aureus (9%) and 28% of patients died within 30 days 
of their positive blood culture [30].
Herpes virus reactivations and infections are increased in both 
patients with treatment naive and treated CLL. Varicella zoster is 
an important complication with both localized dermatome-restricted 
infections (shingles) and disseminated varicella. Shingles has been 
reported at rate of 3.1/100 patient-years with most (90%) being 
considered minor infections (grade <3) but with the potential to cause 
serious long-term neuropathy [3]. Disseminated varicella zoster is a 
rare but serious complication of CLL and its treatment [31].
Herpes simplex reactivation can cause serious complications in 
patients with CLL. Treatment naive patients have an increased 
rate of reactivation and this risk is significantly increased by 
immunosuppressive therapy [32]. Of particular concern is systemic 
dissemination causing severe illness. CLL patients also appear 
to have an increased risk of herpes simplex adenitis that can be 
clinically indistinguishable from transformation to diffuse large B-cell 
lymphoma (DLBCL) [33, 34]. Fortunately, this condition is usually 
rapidly responsive to anti-viral therapy.
Cytomegalovirus (CMV) reactivation can occur in treatment naive 
CLL patients, and the risk is increased in patients receiving highly 
immunosuppressive therapy and especially alemtuzumab [32]. 
Serious morbidity and mortality from CMV reactivation in high-risk 
CLL patients can be decreased by monitoring for CMV viremia and 
treating positive patients.
There is increasing data on the infectious complications in patients 
treated with targeted therapy. The 5-year follow-up data from studies 
of ibrutinib monotherapy in both treatment naive patients and 
relapsed/refractory (R/R) CLL showed a cumulative rate of grade 3 
or higher infections of 42% at 3 years and 48% at 5 years with more 
cases in patients with R/R disease [35]. The most common infections 
were pneumonia, cellulitis, and sepsis. There have been concerns 
that ibrutinib could increase the risk of fungal infections in patients 
with CLL. Although atypical pneumonia caused by Pneumocystis 
jirovecci pneumonia (PJP) was reported in CLL patients on ibrutinib 
therapy, these infections were either asymptomatic (detected by 
routine CT scans) or caused only minor symptoms and responded 
to oral therapy [36]. PCP prophylaxis is currently not recommended 
[37]. Aspergillus infections could be a concern for patients treated 
with ibrutinib in combination with corticosteroids or with other 
additional causes of immunocompromise [38]. Reactivation of 
herpes virus infections and hepatitis B are rare in patients on ibrutinib 
monotherapy [29].
In contrast to ibrutinib, rates of infectious complications for CLL 
appear to be increased by regimens including idelalisib. Combination 
therapy clinical trials including idelalisib were halted by the Federal 
Drug Administration and European Drug Agency because of 
concerns for excess toxicity including increased rates of PJP and 
CMV infections [29]. There are limited data on the effect of duvelisib 
and umbralisib on risk of infection in CLL patients.
Management
Management of infection in CLL patients requires education of 
patients and care givers to respond rapidly to evidence of infection, 
appropriate vaccination, and prophylactic antimicrobial and 
immunoglobulin replacement therapy, and rapid recognition and 
aggressive treatment of serious infections by health care providers.
Vaccination
CLL patients should not get live vaccines but could benefit from 
inactive vaccines despite the generally poorer immune responses 
than in people without CLL. The pneumococcal conjugate vaccine 
(PCV) response rate is ~40% in early-stage CLL patients and 
protection can persist for more than 5 years [39]. The 23-valent 
pneumococcal polysaccharide vaccine (PPV23) generates poorer 
responses in CLL patients [39, 40] but is still considered protective 
and is recommended every 5 years [30]. The annual influenza vaccine 
is recommended for all CLL patients despite decreased efficacy [30] 
and limited data suggest that vaccine responses are not decreased 
by ibrutinib therapy [41].
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Immunoglobulin replacement therapy
CLL is characterized by hypogammaglobulinemia that can worsen 
with progression of disease and treatment [13]. A series of 
randomized trials with short follow-up done in the 1980s and 1990s 
showed that intravenous immunoglobulin (IVIG) replacement therapy 
decreased the incidence of bacterial infections in CLL patients with 
hypogammaglobulinemia or a history of recurrent infections but did 
not significantly alter overall survival [13]. There are no validated 
criteria for use of immunoglobulin replacement therapy but consensus 
opinions include recommendations of supplementation in patients 
with hypogammaglobulinemia and two or more infections requiring 
antibiotics in 1 year [30].
Second Malignancies
Patients with CLL have an increased risk of second malignancies 
that can be the most common cause of death in some populations [5, 
42]. A recently published report from the Swedish national CLL cohort 
included over 18,000 patients showed a 2-fold overall increase risk of 
a second cancer [43].
Skin cancer
The most common nonhematological malignancies in CLL patients 
involve the skin with an increase in relative risk for invasive 
nonmelanoma skin cancer of 24.5 for in situ and 7.6 for invasive 
nonmelanoma skin cancer, and an increased relative risk of 
melanoma of 3.2 [43].
Nonmelanoma skin cancer
CLL patients have an increased risk of both basal cell and squamous 
cell carcinoma that are likely to be more aggressive and can be 
metastatic [44]. There is also an increased risk of the rarer Kaposi 
sarcoma (relative risk 6.8) [43].
Melanoma
A recently published study of a single institution cohort showed that 
18 (4%) of 470 patients seen over 16 years had 22 melanomas [45]. 
Compared to a matched CLL population from the U.S. Surveillance, 
Epidemiology, and End Results (SEER) database, the standardized 
ratio of invasive melanoma was significantly increased at 6.3 (95% CI 
3.5–10.6) [45]. Most of the melanomas (77%) were diagnosed during 
recommended regular skin evaluation, only 12% of melanomas were 
advanced stage, and 45% of patients were CLL treatment naïve [45].
Other Nonhematological Cancers
Large population-based studies of CLL patients show a significantly 
higher risk of malignancies of the lungs, kidneys, colon, thyroid, 
salivary glands, head and neck, and central nervous system, renal 
cell, and Merkel cell carcinoma and sarcoma [42, 43].
Hematological malignancies
Second lymphoid malignancies: Patients with CLL have a significantly 
increased risk of additional non-Hodgkin lymphoma (relative risk 
3.1) and Hodgkin lymphoma (relative risk 7.1) [43]. These second 
malignancies can be clonally related to their CLL or represent de-
novo lymphoid disease.
Diffuse large B cell lymphoma (DLBCL) also known as classical 
Richter syndrome [46] occurs in 2%–8% of patients with CLL [46]. 
These DLBCL can arise in CLL patients by transformation of a CLL 
cell (80%) or a de novo event resulting in a clonally unrelated disease 
(20%) [47]. The risk of transformation to DLBCL in CLL patients is 
significantly increased in patients with TP53 disruption and NOTCH1 
mutation [47]. Diagnosis of DLBCL in patients with CLL can be 
challenging. DLBCL needs to be distinguished from clonal evolution 
of CLL to a more aggressive disease histologically different from 
DLBCL and characterized by larger and more rapidly dividing cells in 
enlarged nodal proliferation centers. This discrete histological entity 
can occur spontaneously or during treatment with targeted therapy 
[46, 48]. In addition, patients with an established diagnosis of CLL 
can have an increasing number of circulating prolymphocytes over 
time, which is often associated with acquired TP53 defects and MYC 
translocations [49, 50]. Although this condition has previously been 
described as “prolymphocytic transformation,” it is not a discrete 
disease entity and clearly different from primary B-cell prolymphocytic 
leukemia [46].
Diagnosis of Richters syndrome in patients with CLL can be difficult. 
The negative predictive value of 18FDG PET/CT scans is over 97% 
for DLBCL in CLL patients and this imaging modality is also useful in 
selecting the most appropriate site for biopsy when highly FDG avid 
tissue is found [47]. Definitive diagnosis of DLBCL requires excision 
biopsy of a lymph node or large excision biopsy of involved tissue 
[51]. In patients with a diagnosis of DLBCL, VDJ rearrangement 
analysis or IGHV sequencing is then required to distinguish between 
DLBCL clonally related to the patients CLL and a clonally unrelated 
de novo DLBCL. Clonally related DLBCL has a gene expression 
profile distinct from de-novo DLBCL [47], no established treatment 
options and poor prognosis (median survival < 1 year) [41, 46]. The 
less common clonally unrelated DLBCL have similar biology and 
outcome to DLBCL arising in patients with no pre-existing lymphoid 
malignancy [46].
Hodgkin lymphoma occurs in <1% of CLL patients [46]. There is 
limited data on optimal treatment and median survival of 4 years is 
shorter than de-novo classical Hodgkin lymphoma [47].
Myeloid malignancies: Studies of large populations of CLL patients 
have not shown an increase in incidence of acute myelogenous 
leukemia [42]. However, combination chemotherapy including purine 
analoges and alkylating agents could increase the risk of treatment-
related myelodysplastic syndrome/acute myeloid leukemia [52].
Management
Patients and their care providers need to be educated about 
risk prevention and monitoring. Patients should avoid ultraviolet 
irradiation by wearing protective clothing and using effective 
sunscreens. Patients are advised to do monthly skin checks and be 
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followed by a dermatologist at least annually. Patients should avoid 
other known carcinogens and especially tobacco and excessive 
alcohol. Patients and their families should be educated about the 
clinical manifestations of CLL transformation.
Autoimmune diseases
Patient with CLL have a significant increase in the rate of autoimmune 
cytopenias. CLL is not associated with an increased risk of the more 
common nonhematological autoimmune diseases [53]. Autoimmune 
cytopenias include autoimmune hemolytic anemia (AIHA), immune 
thrombocytopenia (ITP), pure red blood cell aplasia (PRBCA), and 
autoimmune neutropenia. In >90% of patients, AIHA and ITP are 
caused by high-affinity polyclonal IgG produced by nonmalignant 
B cells implying a loss of self-tolerance by an as yet undefined 
mechanism [54]. A minority of patients have AIHA or ITP caused 
by monoclonal autoantibodies synthesized by the CLL cells. PRBC 
and autoimmune neutropenia can be caused by humoral or cellular 
(T-cell-mediated) cytotoxicity [54].
Autoimmune cytopenia can occur at any time in the course of CLL 
and in 25% of cases can precede or be concomitant with CLL [4]. 
Autoimmune cytopenia does not have the same adverse prognostic 
significance as bone marrow failure [4, 55–60]. This important 
clinical distinction is now recognized in the IWCLL recommendations 
for evaluation and treatment of progressive CLL [61]. However 
autoimmune cytopenia can be a serious and even fatal complication 
of CLL [62].
Autoimmune cytopenia incidence in CLL patients is ~0.5% per year 
[62] and causes ~25% of non-iatrogenic cytopenia [4]. AIHA (55%) 
is the most common presentation followed by ITP (47%), PRBCA 
(12%), and autoimmune neutropenia (4%). More than 10% of 
patients have more than one cytopenia with the most common being 
Evans syndrome (AIHA and ITP) [62].
CLL patients are at increased risk of paraneoplastic pemphigus 
[44], glomerulonephritis [63], and angioedema caused by C1q 
inhibitor deficiency [64]. CLL patients also have an increased risk of 
exaggerated arthropod reactions especially after mosquito bites that 
can lead to loss of skin integrity and serious skin infections [3, 44].
Management
Appropriate management of autoimmune cytopenia requires 
an accurate assessment of etiology by examination of the bone 
marrow. Concomitant extensive bone marrow involvement by CLL 
(bone marrow index <15%) suggests a “complex” etiology requiring 
treatment for both the autoimmune cytopenia and progressive CLL. In 
contrast, patients with adequate bone marrow reserve have “simple” 
autoimmune cytopenia and do not require CLL directed therapy [4, 
65]. Effective therapies for AIHA and ITP include corticosteroids, 
rituximab, and alkylating agents and PRBCA and autoimmune 
neutropenia can be responsive to cyclosporine and corticosteroids 
[66, 67]. Ibrutinib therapy does not appear to be associated with an 
increased risk of autoimmune disease and the drug has been used 
in the therapy of patients with CLL with generally good outcomes and 
can decrease the duration of immunosuppressive therapy [68-71].
Conclusion
CLL is a complex medical disease affecting the hematopoietic and 
immune systems resulting in complicating pathologies that cause 
considerable morbidity and mortality. Improving patient outcome 
requires preventative education and interventions, and active 
monitoring for early recognition and management of complications. 
This requires a team comprising the patients and their caregivers and 
dedicated health care providers. Research efforts should focus on 
better definition of the immune deficits induced by CLL and methods 
to restore immune competence in patients responsive to therapy.
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